Twist Bioscience establishes a new company Revealar Biotherapeutics to develop and commercialize antibody therapies for COVID-19 and other refractory diseases

South San Francisco, California--(BUSINESS WIRE)--November 15, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers obtain A successful company, the company announced today that it has established Revealar Biotherapeutics, Inc.

Dr.

David Scheer, Chairman of the Board of Directors of Revelar Biotherapeutics, said: "We believe that the SARS-CoV-2 therapeutic antibody has the potential for subcutaneous administration.

Twist Bioscience granted Revealar an exclusive license to develop antibody leads and a series of alternate compounds for the potential treatment of SARS-CoV-2

Twist has pledged to invest up to US$10 million as seed funding based on Revealar’s ​​progress in the development of antibody precursors and potential licenses for other antibody therapies

Revelar's executive leadership team includes Glenn Marina (CEO), Kevin Malobisky (Chief Regulatory and Quality Officer), Laurence Smith (CFO and General Counsel), and Rodrigo Mesquita (Vice President of Operations and Project Management)

Glenn Marina, CEO of Revelar, said: "Based on data in a peer-reviewed paper published in Science, Twist Biopharma has optimized an antibody that neutralizes all known SARS-CoV-2.

About Revealar Biotherapeutics

Revelar Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of breakthrough therapeutic antibody products to address important unmet patient needs in COVID-19 and other therapeutic areas

About Twist Bioscience

Twist Bioscience is a leading and fast-growing synthetic biology and genomics company.

Legal statement for forward-looking statements

This press release contains forward-looking statements